Mereo BioPharma (MREO) Total Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Total Liabilities data on file, last reported at $6.6 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $6.6 million, down 20.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (down 20.4% YoY), and the FY2025 annual result was $5.0 million, down 67.57% from the prior year.
• Total Liabilities climbed to $6.6 million in Q1 2026 per MREO's latest filing, from $5.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $30.7 million in Q4 2022 and troughed at -$54.7 million in Q3 2023.
• A 5-year average of -$328396.3 and a median of $8.3 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 135.19% in 2024, then tumbled 67.57% in 2025.
• A 5-year view of Total Liabilities shows it stood at $30.7 million in 2022, then sank by 48.08% to $16.0 million in 2023, then dropped by 3.39% to $15.4 million in 2024, then plunged by 67.57% to $5.0 million in 2025, then jumped by 31.17% to $6.6 million in 2026.
• Business Quant data shows MREO's Total Liabilities at $6.6 million in Q1 2026, $5.0 million in Q4 2025, and $7.0 million in Q3 2025.